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Abstract
Background: We previously derived and validated a risk model to estimate mortality probability in children with septic
shock (PERSEVERE; PEdiatRic SEpsis biomarkEr Risk modEl). PERSEVERE uses five biomarkers and age to estimate mortality
probability. After the initial derivation and validation of PERSEVERE, we combined the derivation and validation cohorts
(n = 355) and updated PERSEVERE. An important step in the development of updated risk models is to test their accuracy
using an independent test cohort.
Objective: To test the prognostic accuracy of the updated version PERSEVERE in an independent test cohort.
Methods: Study subjects were recruited from multiple pediatric intensive care units in the United States. Biomarkers were
measured in 182 pediatric subjects with septic shock using serum samples obtained during the first 24 hours of
presentation. The accuracy of PERSEVERE 28-day mortality risk estimate was tested using diagnostic test statistics, and the
net reclassification improvement (NRI) was used to test whether PERSEVERE adds information to a physiology-based scoring
system.
Results: Mortality in the test cohort was 13.2%. Using a risk cut-off of 2.5%, the sensitivity of PERSEVERE for mortality was
83% (95% CI 62–95), specificity was 75% (68–82), positive predictive value was 34% (22–47), and negative predictive value
was 97% (91–99). The area under the receiver operating characteristic curve was 0.81 (0.70–0.92). The false positive subjects
had a greater degree of organ failure burden and longer intensive care unit length of stay, compared to the true negative
subjects. When adding PERSEVERE to a physiology-based scoring system, the net reclassification improvement was 0.91
(0.47–1.35; p,0.001).
Conclusions: The updated version of PERSEVERE estimates mortality probability reliably in a heterogeneous test cohort of
children with septic shock and provides information over and above a physiology-based scoring system.
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Introduction
Heterogeneity is a major feature of pediatric septic shock,
including widely variable mortality risk [1]. In the absence of tools
to accurately assess mortality risk, clinicians have little objective
information to benchmark septic shock outcomes, adjust for risk in
analyses of clinical data, risk stratify patients for interventional
clinical trials, and guide decisions on which patients need the most
aggressive treatment, and which do not. We recently reported the
derivation and validation of the pediatric sepsis biomarker risk
model (PERSEVERE; PEdiatRic SEpsis biomarkEr Risk modEl)
[2]. PERSEVERE was derived using a Classification and
Regression Tree (CART) approach to predict 28-day mortality.
The derivation selected five biomarkers and age, from among
twelve biomarkers (serum proteins) and clinical variables poten-
tially associated with outcome. Importantly, PERSEVERE was
derived using data measured during the first 24 hours of
presentation to the pediatric intensive care unit (PICU) with
septic shock, which is an optimal time for risk stratification. In
addition, participants were drawn from multiple centers in the
United States [3–5].
Updating risk models using larger learning data sets can
enhance generalizability and reliability. After the initial derivation
and validation of PERSEVERE, we therefore combined the
derivation and validation cohorts (n = 355) and updated PERSE-
VERE [2]. The purpose of the current study is to formally test the
prognostic accuracy of the updated version of PERSEVERE using
an independent test cohort, which is a critical next step after
updating the model. The study is reported following the STARD
(STAndards for the Reporting of Diagnostic accuracy studies)
initiative [6].
Methods
Ethics statement and test cohort study subjects
The test cohort subjects were pooled from four sources, all of
which used the same definition for septic shock [7]. The
Institutional Review Boards (IRB) of each participating institution
approved secondary use of biological specimens and clinical data:
Cincinnati Children’s Hospital Medical Center, The Children’s
Hospital of Philadelphia, Yale University School of Medicine, Ann
& Robert H. Lurie Children’s Hospital of Chicago, Children’s
Hospital and Research Center Oakland, Penn State Hershey
Children’s Hospital, Children’s Mercy Hospital, Children’s
Hospital of Orange County, Akron Children’s Hospital, Nation-
wide Children’s Hospital, Children’s National Medical Center,
Morgan Stanley Children’s Hospital, Columbia University Med-
ical Center, Miami Children’s Hospital, Texas Children’s
Hospital, CS Mott Children’s Hospital at the University of
Michigan, St. Christopher’s Hospital for Children, and Children’s
Hospital of Wisconsin. Written consent was obtained from
the parents or legal guardians of all subjects enrolled. None of
the test cohort subjects were included in the original derivation or
validation of PERSEVERE.
Eighty-seven subjects were included from an ongoing genomics
study in pediatric septic shock being conducted at 17 participating
institutions [8–17]. Briefly, children #10 years of age admitted to
the PICU and meeting pediatric-specific criteria for septic shock
were eligible for enrollment. After written informed consent from
parents or legal guardians, serum samples were obtained within
24 hours of initial presentation to the PICU with septic shock. The
current analysis included subjects enrolled between September
2011 and May 2013.
Sixty subjects were included from among those enrolled in an
ongoing, quality improvement program at Cincinnati Children’s
Hospital Medical Center (CCHMC), Cincinnati, Ohio. The
program uses PERSEVERE to benchmark septic shock outcomes
for all patients admitted to the CCHMC PICU with septic shock.
Enrollment procedures are identical to those described above,
except that there is no age restriction and the CCHMC IRB has
granted permission for waiver of informed consent. Serum samples
are collected from residual blood samples in the clinical
laboratory. Subjects from this source were enrolled between
May 2012 and May 2013.
Nineteen subjects (age range: 8 days to 18 years) were
participants in a prospective, observational study at Ann & Robert
H. Lurie Children’s Hospital of Chicago, Chicago, Illinois,
evaluating nitric oxide metabolism and mitochondrial function
in children with septic shock [18]. Of the 30 subjects with septic
shock enrolled in that study, 19 had serum samples available for
analysis. The current analysis included subjects enrolled between
May 2009 and June 2010.
Sixteen subjects (age range: 2 to 20 years old) were participants
in a prospective, observational study at Yale-New Haven
Children’s Hospital, New Haven, Connecticut, evaluating angio-
poietin levels in children with septic shock [19]. Of the 17 subjects
with septic shock enrolled in that study, 16 had serum samples
available for analysis. The current analysis included subjects
enrolled between September 2009 and December 2011.
Study procedures
For all studies, annotated clinical and laboratory data were
collected daily while the participant was in the PICU. Illness
severity was calculated prospectively using the Pediatric Risk of
Mortality (PRISM) score [20]. The number of organ failures
during the initial 7 days of PICU admission was recorded using
pediatric-specific criteria [7]. PICU free days were calculated by
subtracting the actual PICU length of stay from a theoretical
maximum PICU length of stay of 28 days. Patients with a PICU
length of stay greater than 28 days and patients who died during
the 28-day study period were classified as having zero PICU free
days. All-cause mortality was tracked up to 28 days after meeting
criteria for septic shock.
Biomarkers
PERSEVERE includes C-C chemokine ligand 3 (CCL3),
interleukin 8 (IL8), heat shock protein 70 kDa 1B (HSPA1B),
granzyme B (GZMB), and matrix metallopeptidase 8 (MMP8).
Serum concentrations of these biomarkers were measured using a
multi-plex magnetic bead platform (MILLIPLEXTM MAP)
designed for this project by the EMD Millipore Corporation
(Billerica, MA). Biomarker concentrations were measured in a
LuminexH 100/200 System (Luminex Corporation, Austin, TX),
according the manufacturers’ specifications. Assay performance
data were previously published [2].
Statistical Analysis
Initially, data are described using medians, interquartile ranges,
frequencies, and percentages. Comparisons between groups used
the Mann-Whitney U-test, Chi-square, or Fisher’s Exact tests as
appropriate. Descriptive statistics and comparisons used SigmaStat
Software (Systat Software, Inc., San Jose, CA).
CART analysis was used to derive, validate, and update
PERSEVERE (Salford Predictive Modeler v6.6, Salford Systems,
San Diego, CA) [2,21,22]. Performance of the resulting decision
tree in this new test cohort is reported using diagnostic test
statistics with 95% confidence intervals computed using the score
Sepsis Risk Model
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method as implemented by the VassarStats Website for Statistical
Computation [23]. The net reclassification improvement (NRI)
was used to estimate the incremental predictive ability of the
biomarker-based model compared to using PRISM scores alone
[24]. The NRI was computed using the R-package Hmisc.
Results
Characteristics of the derivation and validation cohorts
Table 1 describes the new test cohort (n = 182), and compares
this to the previously published derivation cohort (n = 355). The
test cohort had a higher median age and a greater proportion of
subjects with no race reported. No other differences were
observed. Within the test cohort, the only difference between
survivors and non-survivors was the median PRISM score.
Testing the model
The test cohort subjects were classified based on the decision
rules of the updated model, without any modifications. Figure 1
shows the classification of the test cohort subjects according to the
updated decision tree, which includes three low risk terminal
nodes (TN2, TN4, and TN7; mortality probability 0.000 to 0.025),
three intermediate risk terminal nodes (TN1, TN3, and TN5;
mortality probability 0.182 to 0.267), and two high-risk terminal
nodes (TN6 and TN8; mortality probability 0.472 to 0.625). There
were 123 test cohort subjects classified as low risk and 59 subjects
classified as either intermediate or high risk. Among the low risk
subjects, four (3.3%) had died by 28 days. Among the intermediate
and high-risk subjects 20 (33.9%) had died by 28 days. Table 2
shows the diagnostic test characteristics of the decision tree in the
test cohort.
When adding the information in PERSEVERE to the
information in PRISM, the NRI was 0.906 (95% CI: 0.465–
1.350; p,0.001). The NRI is a measure of how much the accuracy
of predicted outcomes is improved when adding information [24].
The NRI ranges between 22 and +2. A score of 22 indicates that
all true positives are reclassified as false negatives and all true
negatives are reclassified as false positives, and no false classifica-
tions are reclassified as true classifications. Conversely, when the
score is 2, adding the information correctly reclassifies every case.
Our results demonstrate that the PERSEVERE provides signif-
icant additional classification value beyond the information
included in PRISM.
Table 1. Demographics and clinical characteristics of the derivation and test cohorts.
Derivation Cohort Test Cohort
All Survivors Non-survivors All Survivors Non-survivors
N 355 314 41 182 158 24
Mortality (%) 11.5 – – 13.2 – –
Median days to death – – 3 – – 4
(IQR) (2–12) (2–6)
Mean days to death 6SD – – 7.568.5 – – 4.664.2
Median age years 2.4 2.5 1.9 5.5 5.6 5.0
(IQR) (0.9–6.1) (1.0–6.3) (0.5–5.6) (1.6–13.0)2 (1.7–13.1) (0.6–9.0)
Median PRISM score 13 12 26 11 11 19
(IQR)1 (7–20) (7–19) (17–36) (9–18) (8–15) (13–25)3
# of males (%) 207 (58) 183 (58) 24 (59) 94 (52) 81 (51) 13 (54)
# of females (%) 148 (42) 131 (42) 17 (41) 88 (48) 77 (49) 11 (46)
# for race (%)
Caucasian 266 (75) 237 (75) 29 (71) 129 (71) 112 (71) 17 (71)
African American 54 (15) 48 (15) 6 (15) 20 (11) 18 (11) 2 (8)
Other 18 (5) 15 (5) 3 (7) 3 (2) 1 (1) 2 (8)
Unreported 17 (5) 14 (4) 3 (7) 30 (16)2 27 (17) 3 (13)
# with gram (+) bacteria (%) 97 (27) 85 (27) 12 (29) 54 (30) 46 (29) 8 (33)
# with gram (2) bacteria (%) 82 (23) 73 (23) 9 (22) 39 (21) 31 (20) 8 (33)
# with viral infection (%) 26 (7) 22 (7) 4 (10) 9 (5) 5 (3) 4 (17)
# with fungal infection (%) 9 (3) 8 (3) 1 (2) 7 (4) 7 (4) 0 (0)
# with no organism isolated (%) 144 (41) 129 (41) 15 (37) 80 (44) 75 (47) 5 (21)
# with any co-morbidity (%) 143 (40) 127 (40) 16 (39) 69 (38) 60 (38) 9 (38)
# with malignancy (%) 34 (10) 31 (10) 3 (7) 16 (9) 15 (9) 1 (4)
# with immune suppression (%)4 29 (8) 26 (8) 3 (7) 17 (9) 13 (8) 4 (17)
1Nineteen subjects (18 survivors and 1 non-survivor) in the test cohort did not have available PRISM scores.
2p,0.05 vs. test cohort.
3p,0.05 vs. respective survivors.
4Refers to patients with immune suppression not related to cancer (for example, those receiving immune suppressive medication for solid organ or bone marrow
transplantation, or those with a primary immune deficiency).
doi:10.1371/journal.pone.0086242.t001
Sepsis Risk Model
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Secondary considerations
In our prior study, we noted that subjects classified as false
positives (i.e. those predicted to die, but who actually survived) had
greater illness severity than the true negative subjects (i.e. those
predicted to survive, who did survive), as measured by PICU
length of stay and organ failure burden [2]. We conducted a
similar secondary analysis for the current test cohort. Table 3
shows that the false positive subjects in the test cohort had greater
illness severity than the true negative subjects as measured by
PICU length of stay, PICU free days, organ failure burden, and
organ failure duration.
Discussion
Risk models require updating and ongoing prospective evalu-
ation in order to enhance generalizability and acceptance. We
have prospectively evaluated the prognostic accuracy of the
updated version of PERSEVERE and found that it estimates
mortality probability reliably in a heterogeneous test cohort.
Among subjects predicted to be at intermediate or high-risk, the
Figure 1. Classification of the test cohort subjects according to the updated version of PERSEVERE. The classification tree consists of 6
biomarker-based decision rules, 1 age-based decision rule, 14 daughter nodes, and 8 terminal nodes. The classification tree includes C-C chemokine
ligand 3 (CCL3), heat shock protein 70 kDa 1B (HSPA1B), interleukin-8 (IL8), granzyme B (GZMB), and matrix metalloproteinase-8 (MMP8). Each node
provides the total number of subjects in the node, the biomarker serum concentration- or age-based decision rule, and the number of survivors and
non-survivors with the respective rates. For consistency, the serum concentrations of all stratification biomarkers are provided in pg/ml. The terminal
nodes are numbered TN1 through TN8, and each terminal node provides the actual mortality and survival rates for the respective test cohort
subjects, as well as the respective mortality probability of the updated decision tree, in parentheses. Terminal nodes 2, 4, and 7 are low risk terminal
nodes (mortality probability 0.000 to 0.025), terminal nodes 1, 3, and 5 are intermediate risk terminal nodes (mortality probability 0.182 to 0.267), and
terminal nodes 6 and 8 are high-risk terminal nodes (mortality probability 0.472 to 0.625). To calculate the diagnostic test characteristics, all subjects
in the low risk terminal nodes (n = 123) were classified as predicted survivors, whereas all subjects in the intermediate and high risk terminal nodes
(n = 59) were classified as predicted non-survivors.
doi:10.1371/journal.pone.0086242.g001
Table 2. Diagnostic test characteristics of the decision tree.
Number of Subjects 182
Overall Predicted Mortality 9.3% (7.2–11.3)
Number of True Positives 20
Number of True Negatives 119
Number of False Positives 39
Number of False Negatives 4
Sensitivity 83% (62–95)
Specificity 75% (68–82)
Positive Predictive Value 34% (22–47)
Negative Predictive Value 97% (91–99)
+Likelihood Ratio (2.4–4.7)
2Likelihood Ratio 0.2 (0.1–0.5)
Area Under the Curve 0.811 (0.704–0.917)
doi:10.1371/journal.pone.0086242.t002
Sepsis Risk Model
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e86242
overall mortality rate was 33.9%, whereas subjects classified as low
risk had an overall mortality rate of 3.3%. This dichotomous
interpretation of PERSEVERE partitions a heterogeneous cohort
of patients with septic shock into two groups having a ten-fold
difference in mortality.
A more comprehensive view of PERSEVERE is to view each
terminal node in the decision tree, and to assign individual patients
with a mortality risk based on the probability of death in that
terminal node. This allows for assigning a range of clinically
relevant mortality probabilities and the ability to partition patients
into low, intermediate, and high-risk groups. Moreover, the current
validation study also demonstrates that PERSEVERE adds
significant prognostic value to a physiology-based scoring system.
PERSEVERE generates reliable mortality risk prediction, but is
imperfect; 21% of the test cohort subjects were false positives. This
is to be expected if therapeutic interventions modify the outcomes
of higher risk patients; the false positive subjects likely represent
patients for whom therapeutic interventions prevented the
predicted death. Support for this assertion is provided by our
secondary analysis of the false positive and true negative patients.
False positive subjects had a greater burden and duration of organ
failure, and a greater PICU length of stay than true negative
subjects, suggesting that PERSEVERE accurately identified
higher acuity patients. Thus, even when the prediction is a false
positive the information is likely clinically relevant.
The current test cohort was significantly older than the
derivation cohort with almost one-third of the subjects being
greater than 10 years of age. The issue of age is particularly
important since the original derivation of PERSEVERE was based
exclusively on children less than or equal to 10 years of age, and
because developmental age strongly influences the host response
during septic shock [13,25]. As well as expanding the likely
generalizability of PERSEVERE to subjects greater than 10 years,
the test cohort was pooled from four different sources, each having
its own unique potential for selection bias. This suggests that
PERSEVERE has the potential for both broad applicability in
pediatric septic shock, as well as having the potential to perform
reliably in future prospective testing.
PERSEVERE has various potential clinical applications. First, it
can be used as a benchmark to objectively evaluate septic shock
outcomes. Poor outcomes in patients with a low PERSEVERE-
based mortality risk, could suggest clinical underperformance and
the need to review the clinical care process, while good outcomes
in patients with a high PERSEVERE-based mortality risk could
indicate better than expected clinical performance. We note that
the actual mortality rate of the test cohort (13.3%) was higher than
the overall mortality predicted by PERSEVERE (9.3%; 95% CI
7.2 to 11.3). This discrepancy reflects the four false negative
classifications in terminal nodes 2 and 7. Three of these deaths
were attributable to a single center, and in the quality peer review
of these subjects, it was deemed that the deaths were unlikely to
reflect a deficit in the care process. All three subjects had ‘‘do not
resuscitate’’ orders in place and died after removal of advanced life
support upon determination by the family and health care team
that further support was futile. Two subjects had chronic multi-
organ dysfunction associated with complications following bone
marrow transplantation. The third subject had a lethal, progres-
sive neurodegenerative disease. This illustrates how PERSEVERE
can lead to a quality review of the care process, and the challenges
inherent to assigning a mortality probability in patients with
complex co-morbidities. Future calibrations of PERSEVERE may
require the consideration of a co-morbidity variable, including
immune function status. We note, however, that many test cohort
subjects with significant co-morbidities (n = 45) or immune
suppression (n = 12) were correctly classified by PERSEVERE.
Second, PERSEVERE could be used to conduct risk-stratified
analyses of clinical data, as demonstrated in a recent study by our
group [26]. We found the influence of positive fluid balance on
pediatric septic shock outcomes to depend on risk as predicted by
PERSEVERE. A positive fluid balance was associated with poor
outcomes in the low mortality risk group, but not in the
intermediate or high mortality risk groups. Third, PERSEVERE
could be used to stratify patients for interventional clinical trials,
and possibly to inform individual patient decision-making. These
two latter applications will require the development of a rapid
assay platform to generate biomarker data in a timely manner. No
assay platform currently exists, but the technology to develop is
readily available.
In conclusion, we have taken an important next step in the
development of PERSEVERE. We have prospectively tested the
prognostic accuracy of the updated version of PERSEVERE and
found that it can be used to assign a reliable mortality probability
in children with septic shock. This tool has various potential
applications in the field of pediatric septic shock.
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Table 3. Clinical course of the true negatives and the false positives.
True Negatives False Positives p value
Number 119 39
Median PICU length of stay, days (IQR) 4 (3–9) 7 (4–13) 0.005
Median PICU free days (IQR) 24 (19–25) 21 (15–24) 0.005
Median maximum number of organ failures (IQR) 1 (1–2) 3 (2–3) ,0.001
Number with $2 organ failures at PICU day 7 (%) 12 (10) 18 (46) ,0.001
doi:10.1371/journal.pone.0086242.t003
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